{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/pelvic-inflammatory-disease/prescribing-information/azithromycin/","result":{"pageContext":{"chapter":{"id":"c6b38292-e76f-5f9e-b08f-9038f7a1e33c","slug":"azithromycin","fullItemName":"Azithromycin","depth":2,"htmlHeader":"<!-- begin field c6658499-ae66-49e3-8792-a9470107298b --><h2>Azithromycin</h2><!-- end field c6658499-ae66-49e3-8792-a9470107298b -->","summary":"","htmlStringContent":"<!-- begin item c5856430-4b1f-4ef9-8137-a947010728bc --><!-- end item c5856430-4b1f-4ef9-8137-a947010728bc -->","topic":{"id":"9f0279a4-2834-5e5a-bcac-8bf82aa33bc3","topicId":"c3fb3eae-a416-4305-9bb7-f8c4a28827e3","topicName":"Pelvic inflammatory disease","slug":"pelvic-inflammatory-disease","lastRevised":"Last revised in June 2019","chapters":[{"id":"5f211e92-2994-512e-b182-200dcee7cfe5","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"1d99b28e-147a-50d9-b809-b2997de385cd","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"edca47ac-ad32-5cdc-b5b0-044c08354023","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"61747f80-342b-5eee-9f57-5585e2e266a1","slug":"changes","fullItemName":"Changes"},{"id":"34323845-1d0f-5dd2-9d12-aa4195ea061a","slug":"update","fullItemName":"Update"}]},{"id":"41aa50e1-c3d6-5af5-8d64-bf56566bcf4a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"5485b6d3-ad41-5a4f-8068-3927541fc840","slug":"goals","fullItemName":"Goals"},{"id":"8e512ac7-b08d-5db9-b36c-0b6bf6adeab6","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"16ee94a8-ef4e-5d73-9aab-3a7ad56481d0","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"00ebd775-876e-52d3-8917-e865f1ca24ac","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"00b18462-2317-5fa1-964d-480008f24d93","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"a76f3e2f-4836-5bfb-8b3d-65126afcd379","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b5957fa8-3b35-540f-93d4-a16fe133bcd7","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"7ffd6d91-45b2-5f09-8a72-1269c1cf4194","slug":"definition","fullItemName":"Definition"},{"id":"8d2eecb8-da49-56f0-b0f3-512e1ef7da78","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"cd56fa88-472b-5053-8750-7288cff96a45","slug":"incidence","fullItemName":"Incidence"},{"id":"eae17c05-1a5f-5d75-be7c-b0e30fbc5151","slug":"complications","fullItemName":"Complications"}]},{"id":"13e64b0f-f012-5f38-978c-906828fd01c0","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"6bef4b1a-5873-5e3c-a07f-a72df2163883","slug":"assessment","fullItemName":"Assessment"},{"id":"44e7ae24-ecb6-5611-a376-e300900a9915","slug":"investigations","fullItemName":"Investigations"},{"id":"f2d53656-5ddd-5cac-a2f0-5155e3e4816f","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"04b9a20a-4646-577d-9db4-a82fad1f1122","fullItemName":"Management","slug":"management","subChapters":[{"id":"db64e69d-0dae-56cc-ac8c-111a4ae832f9","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"c9c97d1d-e768-53f0-8f37-0186133444ed","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"c6b38292-e76f-5f9e-b08f-9038f7a1e33c","slug":"azithromycin","fullItemName":"Azithromycin"},{"id":"33b4bf00-1e15-50d8-ae8e-cae48e64e869","slug":"ceftriaxone","fullItemName":"Ceftriaxone"},{"id":"07bec723-0e9e-5a18-9e33-37a6b08715b1","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"407d577d-6898-50ed-a49b-95ad0651ada7","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"631d3af6-f8a7-581f-9d98-a24412ab54f1","slug":"moxifloxacin","fullItemName":"Moxifloxacin"},{"id":"f5753d3f-d2cb-58c0-a3ba-9ea9ad6651ba","slug":"ofloxacin","fullItemName":"Ofloxacin"}]},{"id":"f7cbd9f8-3abb-50db-95c5-bb3b61731818","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"6b504e72-502e-54b1-8c90-a7bc3421bd9f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"c908da70-e8da-577d-aa14-2a477f0bc1cf","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"07e835ee-992a-5310-a2e1-6c64c3dcf57f","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"81326348-513f-5842-87bb-414706046cb1","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"0f235ae8-132c-5727-bb43-da1eaf2b8a7d","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"c0ba9a54-ce24-5b78-a3fa-c48701375f1c","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"8c22c848-92a6-5535-b584-48002acef06e","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"c9c97d1d-e768-53f0-8f37-0186133444ed","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"c39b16f9-c7f6-57d5-a1aa-1ed13ad6ddd9","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field c01955d8-c397-448b-bbdb-a947015f714c --><h3>What are the contraindications and cautions?</h3><!-- end field c01955d8-c397-448b-bbdb-a947015f714c -->","summary":"","htmlStringContent":"<!-- begin item 8ec87d50-ea22-4798-a1c5-a947015f6fa6 --><!-- begin field 371506fc-468d-4d88-88ad-a947015f714c --><ul><li><strong>Do not prescribe azithromycin to:</strong><ul><li>People with severe hepatic impairment.</li></ul></li><li><strong>Avoid prescribing azithromycin to:</strong><ul><li>Pregnant women — due to the limited data available on the use of azithromycin in pregnant women, the manufacturer advises that it should be avoided unless a suitable alternative is not available.</li><li>Breastfeeding women — the manufacturer advises that azithromycin should be avoided during breastfeeding unless a suitable alternative is not available. If used during breastfeeding, the manufacturer recommends discarding the milk during treatment and for two days after discontinuation of treatment. </li></ul></li><li><strong>Prescribe azithromycin with caution to:</strong><ul><li>People known risk factors for prolongation of the QT interval — very rare cases of QT interval proplongation have been reported in people taking quinolones. Factors that predispose to QT prolongation include:<ul><li>The use of drugs that are known to prolong the QT interval (such as class IA and III anti-arrhythmics, tricyclic antidepressants, macrolides, and antipsychotics).</li><li>Some metabolic disturbances (especially hypokalaemia).</li><li>Congenital long QT syndrome.</li><li>Cardiac disease (for example heart failure, myocardial infarction, bradycardia).</li><li>Female sex.</li><li>Increasing age.</li></ul></li><li>People with:<ul><li>Mild to moderate hepatic impairment.</li><li>Severe renal impairment (estimated glomerular filtration rate [eGFR] less than 10 mL/minute/1.73 m<sup>2</sup>).</li><li>Myasthenia gravis — macrolides may aggravate symptoms.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">BNF 75, 2018</a>]</p><!-- end field 371506fc-468d-4d88-88ad-a947015f714c --><!-- end item 8ec87d50-ea22-4798-a1c5-a947015f6fa6 -->","subChapters":[]},{"id":"4e02fc22-80a0-5abc-817f-7cc1891dc6be","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field fb3ec803-4832-4ddd-81c8-a947015f8660 --><h3>What are the adverse effects?</h3><!-- end field fb3ec803-4832-4ddd-81c8-a947015f8660 -->","summary":"","htmlStringContent":"<!-- begin item 8f7b3584-5242-438d-a0f9-a947015f8567 --><!-- begin field 009634fc-2f97-40e6-840b-a947015f8660 --><ul><li><strong>Adverse effects of azithromycin include:</strong><ul><li><strong>Common or very common</strong> — anorexia, disturbances in taste, arthralgia, disturbances in vision, dizziness, dyspepsia, flatulence, headache, malaise, paraesthesia, and reversible hearing loss (sometimes with tinnitus) after long-term treatment.</li><li><strong>Uncommon</strong> — anxiety, chest pain, constipation, gastritis, hypoaesthesia, leucopenia, oedema, photosensitivity, and sleep disturbances.</li><li><strong>Rare</strong> — agitation.</li><li><strong>Frequency not known</strong> — acute renal failure, convulsions, haemolytic anaemia, interstitial nephritis, smell disturbances, syncope, thrombocytopenia, and tongue discolouration.</li></ul></li><li><strong>Adverse effects of all macrolides include:</strong><ul><li><strong>Common or very common </strong>— abdominal discomfort, diarrhoea, nausea, and vomiting.</li><li><strong>Uncommon</strong> — cholestatic jaundice, hepatotoxicity, and rash.</li><li><strong>Rare</strong> — antibiotic-associated colitis, arrhythmias, pancreatitis, QT interval prolongation, Stevens-Johnson syndrome, and toxic epidermal necrolysis.</li><li><strong>Frequency not known</strong> — reversible hearing loss (sometimes with tinnitus) after large doses.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">BNF 75, 2018</a>]</p><!-- end field 009634fc-2f97-40e6-840b-a947015f8660 --><!-- end item 8f7b3584-5242-438d-a0f9-a947015f8567 -->","subChapters":[]},{"id":"fc876597-aa5e-5e51-a034-3b95ffa2b6a7","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field fa0066e0-be4c-4c71-906b-a947015f9a26 --><h3>What are the drug interactions?</h3><!-- end field fa0066e0-be4c-4c71-906b-a947015f9a26 -->","summary":"","htmlStringContent":"<!-- begin item c3a8ed63-0f90-464f-ba45-a947015f991f --><!-- begin field 07683f0a-6204-47fc-a290-a947015f9a26 --><ul><li><strong>Drug interactions of </strong><strong>azithromycin</strong><strong><strong> incl</strong>ude:</strong><ul><li><strong>Antacids</strong> — plasma concentrations of azithromycin may be reduced by antacids.<ul><li>Advise that azithromycin should be taken at least 2 hours before or 1 hour after antacids</li></ul></li><li><strong>Ciclosporin</strong> — azithromycin can affect clearance of ciclosporin.<ul><li>If co-administration of these drugs is necessary, monitor ciclosporin levels and adjust the dose accordingly.</li></ul></li><li><strong>Colchicine</strong> — azithromycin slightly increases the levels of colchicine.<ul><li>Monitor for signs of colchicine toxicity (for example, nausea, vomiting, diarrhoea, myopathy, and pancytopenia).</li></ul></li><li><strong>Digoxin</strong> — macrolides increase digoxin levels. <ul><li>Monitor and reduce the digoxin dose if required.</li></ul></li><li><strong>Edoxaban</strong> — levels may be increased by azithromycin.<ul><li>Dose adjustment of edoxaban may be required.</li></ul></li><li><strong>Ergot derivatives</strong> — there is a theoretical possibility of ergot toxicity if taken concomitantly with azithromycin.<ul><li>The manufacturer of azithromycin recommends avoiding.</li></ul></li><li><strong>Rifabutin</strong> — azithromycin increases the risk of neutropenia when given with rifabutin.<ul><li>Monitor closely.</li></ul></li><li><strong>Statins</strong> — there is a possible increased risk of myopathy.<ul><li>Advise the person to report any muscle pain, tenderness, or weakness.</li></ul></li><li><strong>Warfarin</strong> — occasionally and unpredictably, the effects of warfarin may be markedly increased by macrolides.<ul><li>Monitor the international normalized ratio (INR), and adjust the warfarin dose accordingly.</li></ul></li><li><strong>Drugs that prolong the QT interval</strong> <strong>(such as amiodarone or sotalol) </strong>— all macrolides can prolong the QT interval, and concomitant use of drugs that prolong the QT interval is not recommended.<ul><li>Use an alternative antibiotic and/or seek advice from a microbiologist.</li></ul></li></ul></li><li><strong>Oral hormonal contraception</strong> — additional contraceptive precautions are <em>not</em> required during or after courses of azithromycin [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">FSRH, 2017</a>].<ul><li>However, advise women on the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the section on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods </a>  and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li><li><strong>For a complete list of possible drug interactions of </strong><strong>azithromycin, </strong>see the <a data-hyperlink-id=\"5203f819-92f2-4ec0-b745-a94a00ee63e5\" href=\"http://scribe.clarity.co.uk/www.medicines.org.uk/emc\">electronic Medicines Compendium</a> (eMC) and the <a data-hyperlink-id=\"3eb72c95-6193-4a8b-81f0-a94a00ee64a5\" href=\"https://bnf.nice.org.uk/\">British National Formulary</a> (BNF).</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">BNF 75, 2018</a>]</p><!-- end field 07683f0a-6204-47fc-a290-a947015f9a26 --><!-- end item c3a8ed63-0f90-464f-ba45-a947015f991f -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}